GLP-1 medications have been in clinical use since 2005 (exenatide) and the modern class since 2010 (liraglutide). The safety profile is well-characterized but not without real risks. Here’s what the data actually shows.
The headline risks
Boxed warning: thyroid C-cell tumors
In rodents, GLP-1 agonists caused medullary thyroid carcinoma (MTC). It is unknown whether this risk translates to humans, but the FDA requires a boxed warning. GLP-1s are contraindicated in anyone with:
- Personal or family history of MTC
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
Pancreatitis
Acute pancreatitis is a known, rare risk (roughly 0.1–0.3% per year of treatment in trials — modestly above placebo). Persistent severe abdominal pain radiating to the back requires immediate evaluation.
Gallbladder disease
Rapid weight loss of any kind increases gallstone risk; GLP-1s appear to compound this. Symptomatic gallbladder disease occurs in 1–2% of long-term users.
Diabetic retinopathy (semaglutide specifically)
Rapid glucose-lowering can worsen pre-existing retinopathy. Patients with diabetic eye disease need ophthalmology monitoring.
Hypoglycemia
GLP-1s alone almost never cause low blood sugar. Combined with insulin or sulfonylureas, they substantially increase the risk — those background doses usually need to be reduced.
Common side effects (and they really are common)
In trials, 60–80% of users experience at least one GI side effect during titration:
- Nausea (40–50%)
- Diarrhea (20–30%)
- Constipation (15–25%)
- Vomiting (15–25%)
- Decreased appetite (almost universal — usually desired)
Roughly 5–10% of users discontinue due to side effects. Most symptoms peak during dose escalation and improve substantially within a few weeks at a stable dose.
Emerging concerns
- Muscle loss. Like any form of significant weight loss, 25–40% of lost mass can be lean tissue. Protein intake (1.2–1.6 g/kg) and resistance training largely prevent this.
- Gastroparesis-like symptoms. A small subset of users develop persistent severe delayed emptying. Often reversible on stopping.
- Suicidal ideation. Investigated by the FDA and EMA; current evidence does not support a causal link, but it remains under monitoring.
- Anesthesia aspiration risk. Pause the drug before elective surgery — current ASA guidance is 1 week for weekly formulations.
Long-term data
We now have:
- Up to 4 years of safety follow-up from the SELECT cardiovascular outcomes trial (semaglutide).
- 2+ years of weight-management data (STEP, SURMOUNT).
- A decade+ of post-marketing data on liraglutide and exenatide.
No new major signals have emerged at these durations. Cardiovascular and renal benefits, however, have grown stronger over time.
Who should not take GLP-1s
- History of MTC or MEN 2
- History of pancreatitis (relative contraindication)
- Severe gastroparesis or active inflammatory bowel disease
- Pregnancy, planning pregnancy in <2 months, or breastfeeding
- Children under 12 (under 10 for Victoza T2D use)
- Type 1 diabetes (no efficacy data; risk of DKA)
Bottom line
For people who meet the indications and tolerate the GI phase, GLP-1s have a favorable risk-benefit ratio supported by large outcomes trials. The risks are real but well-defined and largely monitorable. The dangerous version of these drugs is the unregulated, compounded, or counterfeit version — covered in how to get them. For practical management of common side effects during titration, see our side-effects guide. The FDA maintains an active MedWatch portal for reporting adverse events.